AstraZeneca Loses Bid To Stretch Seroquel Exclusivity
A Washington federal judge has rejected AstraZeneca PLC's bid to overturn the U.S. Food and Drug Administration's approval of generic versions of its antipsychotic Seroquel on grounds that they violate the...To view the full article, register now.
Already a subscriber? Click here to view full article